A phase II study of the somatostatin analog sandostatin LAR in patients with androgen independent prostate cancer
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2013
At a glance
- Drugs Octreotide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Mar 2010 Primary endpoint 'Prostate specific antigen' has not been met.
- 05 Mar 2010 Results presented at ASCO Genitourinary Cancers Symposium 2010.